Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions

Prof Nicolas Girard (Institut Curie, Paris, France), Prof Frank Griesinger (University of Oldenburg, Oldenburg, Germany), Prof Keith Kerr (Aberdeen University Medical School, Aberdeen, UK) and Dr Antonio Passaro (European Institute of Oncology, Milan, Italy) discuss the real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions. Initially, they talk about the difference between exon 20 mutations from the other EGFR mutations. Prof Griesinger then explains the heterogeneity and incidence of these mutations. Prof Kerr discusses the identification procedures for EGFR exon 20 insertions. The panel further evaluates the unmet needs for advanced NSCLC patients with EGFR exon 20 insertions and identifies and reviews the latest advances of the emerging options in these patient populations. They also discuss the new treatment options presented at ELCC 2021 for these patients. They discuss a study for real-world frequency of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations by site of insertion and they also talk about the real-world study of NSCLC with EGFR exon 20 insertions from ELCC 2021. In the end, Prof Girard talks about what we should be looking forward to in the future for EGFR exon 20 NSCLC treatment.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.